

Roy M Gulick

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3080785/publications.pdf>

Version: 2024-02-01

113
papers

14,040
citations

71102

41
h-index

30087

103
g-index

113
all docs

113
docs citations

113
times ranked

17778
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 1 | Clinical Characteristics of Covid-19 in New York City. <i>New England Journal of Medicine</i> , 2020, 382, 2372-2374. | 27.0 | 1,836 |
| 2 | Treatment with Indinavir, Zidovudine, and Lamivudine in Adults with Human Immunodeficiency Virus Infection and Prior Antiretroviral Therapy. <i>New England Journal of Medicine</i> , 1997, 337, 734-739. | 27.0 | 1,823 |
| 3 | Severe Covid-19. <i>New England Journal of Medicine</i> , 2020, 383, 2451-2460. | 27.0 | 1,147 |
| 4 | Maraviroc for Previously Treated Patients with R5 HIV-1 Infection. <i>New England Journal of Medicine</i> , 2008, 359, 1429-1441. | 27.0 | 708 |
| 5 | Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117. <i>Nature</i> , 2015, 522, 487-491. | 27.8 | 665 |
| 6 | Triple-Nucleoside Regimens versus Efavirenz-Containing Regimens for the Initial Treatment of HIV-1 Infection. <i>New England Journal of Medicine</i> , 2004, 350, 1850-1861. | 27.0 | 495 |
| 7 | Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. <i>Aids</i> , 2004, 18, 2391-400. | 2.2 | 429 |
| 8 | HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption. <i>Nature</i> , 2016, 535, 556-560. | 27.8 | 400 |
| 9 | Antibody 10-1074 suppresses viremia in HIV-1-infected individuals. <i>Nature Medicine</i> , 2017, 23, 185-191. | 30.7 | 399 |
| 10 | Combination therapy with anti-HIV-1 antibodies maintains viral suppression. <i>Nature</i> , 2018, 561, 479-484. | 27.8 | 392 |
| 11 | Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women. <i>New England Journal of Medicine</i> , 2021, 385, 595-608. | 27.0 | 359 |
| 12 | Early versus Standard Antiretroviral Therapy for HIV-Infected Adults in Haiti. <i>New England Journal of Medicine</i> , 2010, 363, 257-265. | 27.0 | 329 |
| 13 | Antiretroviral Therapy in a Thousand Patients with AIDS in Haiti. <i>New England Journal of Medicine</i> , 2005, 353, 2325-2334. | 27.0 | 249 |
| 14 | Phase 2 Study of the Safety and Efficacy of Vicriviroc, a CCR5 Inhibitor, in HIV-1-Infected, Treatment-Experienced Patients: AIDS Clinical Trials Group 5211. <i>Journal of Infectious Diseases</i> , 2007, 196, 304-312. | 4.0 | 237 |
| 15 | Simultaneous vs Sequential Initiation of Therapy With Indinavir, Zidovudine, and Lamivudine for HIV-1 Infection. <i>JAMA - Journal of the American Medical Association</i> , 1998, 280, 35. | 7.4 | 228 |
| 16 | Impact of Efavirenz on Neuropsychological Performance and Symptoms in HIV-Infected Individuals. <i>Annals of Internal Medicine</i> , 2005, 143, 714. | 3.9 | 226 |
| 17 | Three- vs Four-Drug Antiretroviral Regimens for the Initial Treatment of HIV-1 Infection<SUBTITLE></SUBTITLE>; A Randomized Controlled Trial<SUBTITLE></SUBTITLE>. <i>JAMA - Journal of the American Medical Association</i> , 2006, 296, 769. | 7.4 | 209 |
| 18 | Pharmacogenetics of Plasma Efavirenz Exposure after Treatment Discontinuation: An Adult AIDS Clinical Trials Group Study. <i>Clinical Infectious Diseases</i> , 2006, 42, 401-407. | 5.8 | 208 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 19 | ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naïve adults with HIV-1 infection: 48-week results. <i>Aids</i> , 2001, 15, F1-F9. | 2.2 | 206 |
| 20 | Quantitative Deep Sequencing Reveals Dynamic HIV-1 Escape and Large Population Shifts during CCR5 Antagonist Therapy In Vivo. <i>PLoS ONE</i> , 2009, 4, e5683. | 2.5 | 205 |
| 21 | Safety and antiviral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals. <i>Nature Medicine</i> , 2018, 24, 1701-1707. | 30.7 | 195 |
| 22 | HIV Type 1 Chemokine Coreceptor Use among Antiretroviral-Experienced Patients Screened for a Clinical Trial of a CCR5 Inhibitor: AIDS Clinical Trial Group A5211. <i>Clinical Infectious Diseases</i> , 2007, 44, 591-595. | 5.8 | 179 |
| 23 | Association Between Efavirenz as Initial Therapy for HIV-1 Infection and Increased Risk for Suicidal Ideation or Attempted or Completed Suicide. <i>Annals of Internal Medicine</i> , 2014, 161, 1. | 3.9 | 175 |
| 24 | Dual vs Single Protease Inhibitor Therapy Following Antiretroviral Treatment Failure<SUBTITLE>A Randomized Trial</SUBTITLE>. <i>JAMA - Journal of the American Medical Association</i> , 2002, 288, 169. | 7.4 | 160 |
| 25 | Raltegravir: The First HIV Type 1 Integrase Inhibitor. <i>Clinical Infectious Diseases</i> , 2009, 48, 931-939. | 5.8 | 135 |
| 26 | The Control of HIV After Antiretroviral Medication Pause (CHAMP) Study: Posttreatment Controllers Identified From 14 Clinical Studies. <i>Journal of Infectious Diseases</i> , 2018, 218, 1954-1963. | 4.0 | 130 |
| 27 | In Vivo Emergence of Vicriviroc Resistance in a Human Immunodeficiency Virus Type 1 Subtype C-Infected Subject. <i>Journal of Virology</i> , 2008, 82, 8210-8214. | 3.4 | 110 |
| 28 | Long-Term Impact of Efavirenz on Neuropsychological Performance and Symptoms in HIV-Infected Individuals (ACTG 5097s). <i>HIV Clinical Trials</i> , 2009, 10, 343-355. | 2.0 | 100 |
| 29 | Long-term safety and durable antiretroviral activity of lopinavir/ritonavir in treatment-naïve patients. <i>Aids</i> , 2004, 18, 775-779. | 2.2 | 98 |
| 30 | Long-Acting HIV Drugs for Treatment and Prevention. <i>Annual Review of Medicine</i> , 2019, 70, 137-150. | 12.2 | 87 |
| 31 | Phase I Studies of Hypericin, the Active Compound in St. John's Wort, as an Antiretroviral Agent in HIV-Infected Adults: AIDS Clinical Trials Group Protocols 150 and 258. <i>Annals of Internal Medicine</i> , 1999, 130, 510. | 3.9 | 85 |
| 32 | Relationship between latent and rebound viruses in a clinical trial of anti-HIV-1 antibody 3BNC117. <i>Journal of Experimental Medicine</i> , 2018, 215, 2311-2324. | 8.5 | 84 |
| 33 | ACTG A5353: A Pilot Study of Dolutegravir Plus Lamivudine for Initial Treatment of Human Immunodeficiency Virus-1 (HIV-1)-infected Participants With HIV-1 RNA ≥ 500000 Copies/mL. <i>Clinical Infectious Diseases</i> , 2018, 66, 1689-1697. | 5.8 | 83 |
| 34 | A comparison of stavudine plus lamivudine versus zidovudine plus lamivudine in combination with indinavir in antiretroviral naïve individuals with HIV infection: selection of thymidine analog regimen therapy (START I). <i>Aids</i> , 2000, 14, 1591-1600. | 2.2 | 76 |
| 35 | Obesity and COVID-19 in New York City: A Retrospective Cohort Study. <i>Annals of Internal Medicine</i> , 2020, 173, 855-858. | 3.9 | 72 |
| 36 | Episomal Viral cDNAs Identify a Reservoir That Fuels Viral Rebound after Treatment Interruption and That Contributes to Treatment Failure. <i>PLoS Pathogens</i> , 2011, 7, e1001303. | 4.7 | 70 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 37 | CCR5 Antagonism in HIV Infection: Current Concepts and Future Opportunities. <i>Annual Review of Medicine</i> , 2012, 63, 81-93. | 12.2 | 60 |
| 38 | Six-year follow-up of HIV-1-infected adults in a clinical trial of antiretroviral therapy with indinavir, zidovudine, and lamivudine. <i>Aids</i> , 2003, 17, 2345-2349. | 2.2 | 52 |
| 39 | HIV treatment and prevention 2019. <i>Current Opinion in HIV and AIDS</i> , 2020, 15, 4-12. | 3.8 | 52 |
| 40 | The Cost-effectiveness and Budget Impact of 2-Drug Dolutegravir-Lamivudine Regimens for the Treatment of HIV Infection in the United States. <i>Clinical Infectious Diseases</i> , 2016, 62, 784-791. | 5.8 | 50 |
| 41 | Competing drug-drug interactions among multidrug antiretroviral regimens used in the treatment of HIV-infected subjects: ACTG 884. <i>Aids</i> , 2000, 14, 2495-2501. | 2.2 | 45 |
| 42 | Antiretroviral therapies for treatment-experienced patients: current status and research challenges. <i>Aids</i> , 2005, 19, 747-756. | 2.2 | 42 |
| 43 | Reanalysis of Coreceptor Tropism in HIV-1-Infected Adults Using a Phenotypic Assay with Enhanced Sensitivity. <i>Clinical Infectious Diseases</i> , 2011, 52, 925-928. | 5.8 | 42 |
| 44 | COVID-19 in Hospitalized Adults With HIV. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa327. | 0.9 | 42 |
| 45 | Racial Differences in Response to Antiretroviral Therapy for HIV Infection: An AIDS Clinical Trials Group (ACTG) Study Analysis. <i>Clinical Infectious Diseases</i> , 2013, 57, 1607-1617. | 5.8 | 40 |
| 46 | PHASE 2 STUDY OF THE SAFETY AND TOLERABILITY OF MARAVIROC-CONTAINING REGIMENS TO PREVENT HIV INFECTION IN MEN WHO HAVE SEX WITH MEN (MSM) (HPTN 069/ACTG A5305). <i>Journal of Infectious Diseases</i> , 2017, 215, jiw525. | 4.0 | 40 |
| 47 | Editorial Commentary: Adherence to Antiretroviral Therapy: How Much Is Enough?. <i>Clinical Infectious Diseases</i> , 2006, 43, 942-944. | 5.8 | 38 |
| 48 | Evidence of Ongoing Immune Reconstitution in Subjects with Sustained Viral Suppression following 6 Years of Lopinavir-Ritonavir Treatment. <i>Clinical Infectious Diseases</i> , 2007, 44, 749-754. | 5.8 | 38 |
| 49 | Convalescent Plasma for the Treatment of COVID-19: Perspectives of the National Institutes of Health COVID-19 Treatment Guidelines Panel. <i>Annals of Internal Medicine</i> , 2021, 174, 93-95. | 3.9 | 38 |
| 50 | Phenome-wide Association Study Relating Pretreatment Laboratory Parameters With Human Genetic Variants in AIDS Clinical Trials Group Protocols. <i>Open Forum Infectious Diseases</i> , 2015, 2, ofu113. | 0.9 | 37 |
| 51 | Invasive Meningococcal Disease in Men Who Have Sex With Men. <i>Annals of Internal Medicine</i> , 2013, 159, 300. | 3.9 | 36 |
| 52 | Five-Year Safety Evaluation of Maraviroc in HIV-1-Infected Treatment-Experienced Patients. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2014, 65, 78-81. | 2.1 | 36 |
| 53 | Survival, plasma HIV-1 RNA concentrations and drug resistance in HIV-1-infected Haitian adolescents and young adults on antiretrovirals. <i>Bulletin of the World Health Organization</i> , 2008, 86, 970-977. | 3.3 | 35 |
| 54 | Efavirenz Pharmacogenetics and Weight Gain Following Switch to Integrase Inhibitor-Containing Regimens. <i>Clinical Infectious Diseases</i> , 2021, 73, e2153-e2163. | 5.8 | 32 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 55 | Structured Treatment Interruption in Patients Infected with HIV. <i>Drugs</i> , 2002, 62, 245-253. | 10.9 | 31 |
| 56 | Change in High-Sensitivity C-Reactive Protein Levels Following Initiation of Efavirenz-Based Antiretroviral Regimens in HIV-Infected Individuals. <i>AIDS Research and Human Retroviruses</i> , 2011, 27, 461-468. | 1.1 | 30 |
| 57 | Substitution of Nevirapine because of Efavirenz Toxicity in AIDS Clinical Trials Group A5095. <i>Clinical Infectious Diseases</i> , 2010, 50, 787-791. | 5.8 | 29 |
| 58 | Next-generation oral preexposure prophylaxis. <i>Current Opinion in HIV and AIDS</i> , 2012, 7, 600-606. | 3.8 | 29 |
| 59 | Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in Women. <i>Annals of Internal Medicine</i> , 2017, 167, 384. | 3.9 | 29 |
| 60 | Current antiretroviral therapy: an overview. <i>Quality of Life Research</i> , 1997, 6, 471-474. | 3.1 | 27 |
| 61 | The Relationship of CCR5 Antagonists to CD4+ T-Cell Gain: A Meta-Regression of Recent Clinical Trials in Treatment-Experienced HIV-Infected Patients. <i>HIV Clinical Trials</i> , 2010, 11, 351-358. | 2.0 | 27 |
| 62 | HIV/AIDS: When to Start Antiretroviral Therapy?. <i>Clinical Infectious Diseases</i> , 2008, 47, 1580-1586. | 5.8 | 26 |
| 63 | Antiretroviral Treatment 2010: Progress and Controversies. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2010, 55, S43-S48. | 2.1 | 23 |
| 64 | Virologic, clinical and immunologic responses following failure of first-line antiretroviral therapy in Haiti. <i>Journal of the International AIDS Society</i> , 2012, 15, 17375. | 3.0 | 23 |
| 65 | Race/Ethnicity and the Pharmacogenetics of Reported Suicidality With Efavirenz Among Clinical Trials Participants. <i>Journal of Infectious Diseases</i> , 2017, 216, 554-564. | 4.0 | 23 |
| 66 | Intensification of a triple-nucleoside regimen with tenofovir or efavirenz in HIV-1-infected patients with virological suppression. <i>Aids</i> , 2007, 21, 813-823. | 2.2 | 22 |
| 67 | Investigational Antiretroviral Drugs: What is Coming Down the Pipeline. <i>Topics in Antiviral Medicine</i> , 2018, 25, 127-132. | 0.1 | 22 |
| 68 | Safety, tolerability, and clinical outcomes of hydroxychloroquine for hospitalized patients with coronavirus 2019 disease. <i>PLoS ONE</i> , 2020, 15, e0236778. | 2.5 | 21 |
| 69 | HIV Treatment Strategies. <i>JAMA - Journal of the American Medical Association</i> , 1998, 279, 957. | 7.4 | 20 |
| 70 | Dolutegravir plus lamivudine for initial treatment of HIV-1-infected participants with HIV-1 RNA ≤ 500 copies/mL: week 48 outcomes from ACTG 5353. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 1376-1380. | 3.0 | 19 |
| 71 | Blood component utilization in COVID-19 patients in New York City: Transfusions do not follow the curve. <i>Transfusion</i> , 2021, 61, 692-698. | 1.6 | 18 |
| 72 | The pharmacokinetics, pharmacodynamics, and mucosal responses to maraviroc-containing pre-exposure prophylaxis regimens in MSM. <i>Aids</i> , 2019, 33, 237-246. | 2.2 | 17 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 73 | Developing Treatment Guidelines During a Pandemic Health Crisis: Lessons Learned From COVID-19. <i>Annals of Internal Medicine</i> , 2021, 174, 1151-1158. | 3.9 | 16 |
| 74 | Antiretroviral Therapy and Efficacy After Virologic Failure on First-line Boosted Protease Inhibitor Regimens. <i>Clinical Infectious Diseases</i> , 2014, 59, 888-896. | 5.8 | 15 |
| 75 | Perspectives of US women participating in a candidate PrEP study: adherence, acceptability and future use intentions. <i>Journal of the International AIDS Society</i> , 2019, 22, e25247. | 3.0 | 15 |
| 76 | Analysis of Virological Efficacy in Trials of Antiretroviral Regimens: Drawbacks of Not Including Viral Load Measurements after Premature Discontinuation of Therapy. <i>Antiviral Therapy</i> , 2002, 7, 271-281. | 1.0 | 14 |
| 77 | Genetic Variation of the Kinases That Phosphorylate Tenofovir and Emtricitabine in Peripheral Blood Mononuclear Cells. <i>AIDS Research and Human Retroviruses</i> , 2018, 34, 421-429. | 1.1 | 13 |
| 78 | Antiretroviral drug activity and potential for pre-exposure prophylaxis against COVID-19 and HIV infection. <i>Journal of Biomolecular Structure and Dynamics</i> , 2022, 40, 7367-7380. | 3.5 | 13 |
| 79 | Design Issues in Initial HIV-Treatment Trials: Focus on Actg A5095. <i>Antiviral Therapy</i> , 2006, 11, 751-760. | 1.0 | 13 |
| 80 | Durability of Response to Treatment among Antiretroviral-Experienced Subjects: 48-Week Results from AIDS Clinical Trials Group Protocol 359. <i>Journal of Infectious Diseases</i> , 2002, 186, 626-633. | 4.0 | 12 |
| 81 | Invasive <i>Aspergillus</i> Sinusitis in Human Immunodeficiency Virus Infection: Case Report and Review of the Literature. <i>Open Forum Infectious Diseases</i> , 2016, 3, ofw135. | 0.9 | 11 |
| 82 | Comparable viral decay with initial dolutegravir plus lamivudine versus dolutegravir-based triple therapy. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 2365-2369. | 3.0 | 11 |
| 83 | Tissue specificity-aware TWAS (TSA-TWAS) framework identifies novel associations with metabolic, immunologic, and virologic traits in HIV-positive adults. <i>PLoS Genetics</i> , 2021, 17, e1009464. | 3.5 | 11 |
| 84 | Frequency of post treatment control varies by antiretroviral therapy restart and viral load criteria. <i>Aids</i> , 2021, 35, 2225-2227. | 2.2 | 11 |
| 85 | HIV treatment 2020: what will it look like?. <i>Journal of the International AIDS Society</i> , 2014, 17, 19528. | 3.0 | 10 |
| 86 | Higher colorectal tissue HIV infectivity in cisgender women compared with MSM before and during oral preexposure prophylaxis. <i>Aids</i> , 2021, 35, 1585-1595. | 2.2 | 10 |
| 87 | Prioritizing clinical research studies during the COVID-19 pandemic: lessons from New York City. <i>Journal of Clinical Investigation</i> , 2020, 130, 4522-4524. | 8.2 | 10 |
| 88 | Cost-effectiveness of Adding an Agent That Improves Immune Responses to Initial Antiretroviral Therapy (ART) in HIV-Infected Patients: Guidance for Drug Development. <i>HIV Clinical Trials</i> , 2012, 13, 1-10. | 2.0 | 8 |
| 89 | Editorial. <i>Current Opinion in HIV and AIDS</i> , 2018, 13, 291-293. | 3.8 | 8 |
| 90 | ART in HIV-Positive Persons With Low Pretreatment Viremia: Results From the START Trial. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 81, 456-462. | 2.1 | 8 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 91 | Genome-Wide Association Study of Human Immunodeficiency Virus (HIV)-1 Coreceptor Usage in Treatment-Naive Patients from An AIDS Clinical Trials Group Study. <i>Open Forum Infectious Diseases</i> , 2014, 1, ofu018. | 0.9 | 7 |
| 92 | New drugs for HIV therapy. <i>Aids</i> , 2002, 16, S135-S144. | 2.2 | 6 |
| 93 | Randomized Pilot Study of an Advanced Smart-Pill Bottle as an Adherence Intervention in Patients With HIV on Antiretroviral Treatment. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, 86, 73-80. | 2.1 | 6 |
| 94 | Brain neurotransmitter transporter/receptor genomics and efavirenz central nervous system adverse events. <i>Pharmacogenetics and Genomics</i> , 2018, 28, 179-187. | 1.5 | 4 |
| 95 | Racial Disparities in Virologic Failure and Tolerability During Firstline HIV Antiretroviral Therapy. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz022. | 0.9 | 4 |
| 96 | The Uncertain Role of Corticosteroids in the Treatment of COVID-19. <i>JAMA Internal Medicine</i> , 2021, 181, 140. | 5.1 | 4 |
| 97 | Failure of chronic hydroxychloroquine in preventing severe complications of COVID-19 in patients with rheumatic diseases. <i>Rheumatology Advances in Practice</i> , 2021, 5, rkab014. | 0.7 | 4 |
| 98 | Selecting Treatments During an Infectious Disease Pandemic: Chasing the Evidence. <i>Annals of Internal Medicine</i> , 2021, 174, 1464-1465. | 3.9 | 4 |
| 99 | No change in health-related quality of life for at-risk U.S. women and men starting HIV pre-exposure prophylaxis (PrEP): Findings from HPTN 069/ACTG A5305. <i>PLoS ONE</i> , 2018, 13, e0206577. | 2.5 | 3 |
| 100 | Antiretroviral Management of Treatment-Naive Patients. <i>Infectious Disease Clinics of North America</i> , 2007, 21, 71-84. | 5.1 | 2 |
| 101 | Prior Case of Resistance on Dolutegravir Plus Lamivudine Dual Therapy. <i>AIDS Research and Human Retroviruses</i> , 2020, 36, 254-255. | 1.1 | 2 |
| 102 | Bone changes with candidate PrEP regimens containing tenofovir disoproxil fumarate and/or maraviroc and/or emtricitabine in US men and women: HPTN 069/ACTG A5305. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 500-506. | 3.0 | 2 |
| 103 | Drug Costs: What Can Infectious Diseases Physicians Do?. <i>Journal of Infectious Diseases</i> , 2020, 221, 681-684. | 4.0 | 1 |
| 104 | HIV: Closing the Mortality Gap. <i>Annals of Internal Medicine</i> , 2021, 174, 1311-1312. | 3.9 | 1 |
| 105 | Sexual behavior and medication adherence in men who have sex with men participating in a pre-exposure prophylaxis study of combinations of Maraviroc, Tenofovir Disoproxil Fumarate and/or Emtricitabine (HPTN 069/ACTG 5305). <i>AIDS and Behavior</i> , 0, , . | 2.7 | 1 |
| 106 | 1721Cost-Effectiveness of Meningococcal Quadrivalent Conjugate Vaccination Campaign among Men Who Have Sex With Men in New York City. <i>Open Forum Infectious Diseases</i> , 2014, 1, S461-S462. | 0.9 | 0 |
| 107 | 1615Pregnancy-Related Outcomes and Mortality in the Years Following Pregnancy among Women Perinatally Infected with HIV â€” New York City, 2005â€”2011. <i>Open Forum Infectious Diseases</i> , 2014, 1, S431-S431. | 0.9 | 0 |
| 108 | Managing HIV Treatment Failure: Time to REVAMP?. <i>Annals of Internal Medicine</i> , 2021, , . | 3.9 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 109 | A Conversation Among the IAS-USA Board of Directors: Hot Topics and Emerging Data in HIV Research and Care. Topics in Antiviral Medicine, 2017, 24, 142-151. | 0.1 | 0 |
| 110 | Title is missing!. , 2020, 15, e0236778. | | 0 |
| 111 | Title is missing!. , 2020, 15, e0236778. | | 0 |
| 112 | Title is missing!. , 2020, 15, e0236778. | | 0 |
| 113 | Title is missing!. , 2020, 15, e0236778. | | 0 |